INTRODUCTION
Parkinson's disease (PD), mainly resulting from the degeneration of the nigrostriatal dopaminergic system, is a progressive neurodegenerative disorder that affects 2 % of the population over 65 years of age.
Currently the most efficient therapeutic treatment, L-DOPA, aims at replenishing the amount of dopamine missing in the striatum. However, this strategy slowly becomes less effective after long-term treatment and shows undesirable side effects [1, 2] . Cell therapy is an alternative strategy to treat PD and many clinical studies using foetal dopaminergic cells or dopamine-producing cells, such as adrenal chromaffin cells and human retinal pigment epithelium have been performed [3] [4] [5] . These studies gave encouraging results that have provided the proof of principle for cell therapy in PD. However, the outcome was also highly variable between patients and the foetal grafts raised ethical and practical concerns [6] , with a poor survival after transplantation [7] [8] [9] [10] . Stem cells, that can self renew and further differentiate into dopaminergic precursors are currently the most studied candidates for cell therapy in PD. However, due to the difficulties in obtaining neural stem cells from adults and the inherent ethical problems to the use of foetal cells or of embryonic stem cells, multipotent mesenchymal stromal cells (MSCs), may represent an alternative cell source to repair the nervous system [5] .
Indeed, as they are easily isolated from the bone marrow, autologous grafts can be performed avoiding ethical and availability concerns. MSCs may differentiate into progeny of the three embryonic layers in vitro, including neuronal-like cells, under the influence of matrix molecules and growth factors [11] [12] [13] [14] . Using appropriate driving cues, these cells that may partially originate from the neural crest [15] , can be further directed toward a dopaminergic phenotype [16] [17] [18] . Recently, mesenchymal stem-like cells from endometrial origin have also been described as an interesting source of cells for PD therapy due to their ability to produce TH and restore dopamine level in parkinsonian mice [19] . In addition to their neuronal differentiation potential, MSCs posses immunomodulatory properties [20, 21] and have the ability to migrate towards sources of lesions in the brain [22] [23] [24] [25] [26] . Furthermore, some studies showed a functional improvement in the rotational behavior of hemiparkinsonian rats upon transplantation of rat or human MSCs [27] [28] [29] [30] . As only a very small number of neuronallike cells were observed in the brain [29] , these effects were mostly attributed to the ability of MSCs to secrete various growth factors that protected the degenerating neuronal fibres. These reports encourage further studies with MSCs for cell therapy of PD, but also highlight the need to enhance MSC cell engraftment.
Tissue engineering, which combines cells with a supportive scaffold providing a 3D structure, may help to improve cell engraftment after transplantation [5, 31] . In this way, microcarriers transporting foetal ventral mesencephalic (FVM) cells or adrenal chromaffin cells improved their long-term survival after intracerebral transplantation in hemi-parkinsonian rats [32] [33] [34] . A clinical trial has also reported the safety and efficacy of gelatine microcarriers conveying human retinal pigment epithelial cells for the treatment of PD [35, 36] .
Scaffolds providing a biomimetic surface of different extracellular matrix (ECM) molecules or their derived peptides, that stimulate cell survival and differentiation, may further enhance cell engraftment [5, 37] . In this regard, various studies report that laminin (LM) enhances neurite outgrowth of neurons [38] as well as neural stem cell proliferation [39] . In addition, LM may also improve the integration of transplanted cells and their tissue regeneration potential in an ex vivo model of Parkinson's disease [40] . Finally, this ECM molecule is known to affect stem cell motility [41] and differentiation of MSCs towards a neuronal phenotype, in terms of morphology [42] but also of marker expression [43] .
Another way to improve the efficiency of cell grafts is to engineer a scaffold that not only provides a biomimetic surface but also delivers a relevant bioactive growth factor that is released in a controlled manner, further affecting the fate of both transplanted and host cells (see for review [5, 31, 37] ). Indeed, synergistic effects between adhesion and growth factor signals to guide and enhance cell differentiation have now been described [44] . In this sense, we have developed an adaptable and efficient device for tissue engineering, the pharmacologically active microcarriers (PAMs). They are biodegradable and non-cytotoxic polymeric microcarriers made of poly(lactic-co-glycolic acid) (PLGA), that with a functionalized surface provide an adequate 3D support for cell culture and/or for their administration. Their microcarrier role, the biomimetic surface and the programmed delivery of an appropriate therapeutic factor may act synergistically to induce and further maintain the survival and/or differentiation of the transplanted cells and their microenvironment, therefore enhancing their engraftment after complete degradation of the vector [45, 46] . The efficacy of this tool was previously demonstrated in a rat PD paradigm using PAMs conveying PC12 cells and releasing nerve growth factor [47] , but also with FVM cells attached to PAMs releasing glial cell line-derived neurotrophic factor [48] . In both cases, the PAMs stimulated cell survival and differentiation leading to an improved behavior of the animals.
The main goal of this study was to improve MSC survival, differentiation and tissue repair function after implantation in the striatum of hemi-parkinsonian rats, using PAMs tailored for this application. We chose to work with a homogeneous and well characterized subpopulation of human MSCs that express pluripotent stem cells markers. These cells termed "marrow-isolated adult multilineage inducible" (MIAMI) cells, may generate mature cells derived from all three embryonic germ layers [49, 50] . EGF is now considered as an important factor able to enhance the therapeutic potential of MSCs (see for review Tamama et al. [51] ). We recently demonstrated that exposing MIAMI cells to an EGF and bFGF pre-treatment enhances their neural specification and response to neuronal commitment [11] . MIAMI cells further differentiate toward the neuronal lineage on a fibronectin surface in a NT3-dependent manner [16] and this molecule increases β3-Tubulin expression by MIAMI cells [11] and MSCs [52] during in vitro neuronal differentiation. These results appoint NT3 as an ideal protein to encapsulate into PAMs and to use in combination with EGF-bFGF pre-treated MIAMI cells induced towards a dopaminergic phenotype. In order to choose the appropriate biomimetic surface for PAMs, we first screened the panel of integrins expressed by MIAMI cells by RT-qPCR and flow cytometry. We then studied the effect of LM, compared to fibronectin (FN), on the in vitro neuronal differentiation potential of MIAMI cells in terms of cell proliferation, cell length and expression of neuronal markers. Based on these results, PAMs with a biomimetic surface of LM and poly-D-lysine (PDL) were formulated and their total charge as well as the homogeneity of the LM biomimetic surface was characterized by zetametry and immunofluorescence imaging.
PAMs delivering NT3 were formulated and the NT3 release kinetics characterized in vitro. These combined properties should act together to stimulate the survival and differentiation of the grafted MIAMI cells toward a neuronal phenotype. After adhesion of MIAMI cells to PAMs, these complexes were first characterized in vitro.
Next, using a rat partial progressive 6-OHDA model of PD their effects on MIAMI cell survival and differentiation as well as on the motor behavior of the animals and tissue repair/protection were further evaluated.
MATERIALS AND METHODS

Bone marrow harvesting, selection & expansion of MIAMI cells
Whole bone marrow was obtained from vertebral bodies (T1-L5) of a 3 year old male cadaveric donor following guidelines for informed consent set by the University of Miami School of Medicine Committee on the Use of Human Subjects in Research. As previously described [49] under hypoxic conditions. Cells were fed every 2-3 days by changing half the medium and split every 5 days, keeping 1/4 of old medium.
Neuronal differentiation in vitro
To assess the effects of the extracellular matrix molecules on the 3-step in vitro neuronal differentiation of MIAMI cells (passage 4-5) they were first expanded for 10 days in DMEM-low glucose with 20 ng/mL of both EGF and bFGF, 5 µg/mL heparin and a mixture of lipids (working concentration of 510 nM lipoic, 70 nM linolenic and 150 nM linoleic acid, all from Sigma) (pre-treatment step). As previously described [11] , the protocol continued with the 3-step neuronal differentiation by plating the cells at 3000-4000 cells/cm 2 on either FN or LM (from human placenta, Sigma) coated dishes (all at 2 µg/cm²) in DMEM-F12 (GIBCO) medium supplemented with 20 % FBS, 20 ng/mL of both EGF-bFGF, 5 µg/mL heparin, antibiotics and cultured for 24 h in a normoxic atmosphere (Neural specification, step 1). Coating molecules were diluted in Dulbecco's phosphate buffered saline (DPBS) (without Ca and Mg) and coating was made in presence of 1 mM CaCl 2 for LM as it was previously reported to enhance its stabilization [53] . When plated on glass slides, LM coating was made at 0.5 µg/cm² as it allowed a sufficient attachment of cells during differentiation. At the end of step 1, cells were washed and neuronal commitment (step 2) was induced by exposing the cells to 1 mM β-mercaptoethanol figure 3A) . Pre-treated cells were plated (3000-4000 cells/cm²) on a 2 µg/cm² LM substrate in DMEM-F12 containing 20 % FBS, 20 ng/mL of both EGF-bFGF and 5 µg/mL heparin for 24 hours. Medium was then replaced by DMEM-F12 containing 200 ng/mL SHH and 100 ng/mL FGF8b for another 24 hours (both from R&D Systems). Finally, cells were exposed to 0.5 µM retinoic acid (Sigma) during the last 24 hours before attachment to PAMs.
Immunocytofluorescence & cell length analyses in vitro
Cells were plated on coated glass slides for NFM and β3-Tubulin immunocytofluorescence staining at the end of the neuronal differentiation protocol. After washing twice with DPBS, cells were fixed with 4 % 
Reverse transcription and real-time quantitative PCR
Design of primers specific for human genes and PCR were performed as described elsewhere [11] (table   1) and Heat shock 90 kD protein 1 beta (Hspcb, NM_007355) were tested for normalization. The GeNorm™ freeware (http://medgen.ugent.be/~jvdesomp/genorm/) was used to determine that Gapdh, Hprt1 & Hspcb were the three most stable housekeeping genes. The relative transcript quantity (Q) was determined by the delta cT method Q=E (Ct min in all the samples tested-Ct of the sample) where E is related to the primer efficiency (E=2 if the primer efficiency=100 %). Relative quantities (Q) were normalized using the multiple normalization method described in Vandesompele et al. [54] . Q normalized = Q/(geometric mean of the 3 most stable housekeeping genes Q).
Integrin screening by flow cytometry
Cells were washed with DMEM-low glucose and detached with 10 mL Versene (Lonza) for 20 min at 37°C. After pelleting at 295 g for 10 min, cells were washed twice before distribution in 296 well plates ( Every washing step was performed with DPBS, 5 % FBS, 0.02 % azide. Fluorescent signal was acquired using a FACScalibur flow cytometer (BD Biosciences) and data analysis was performed using the Cellquest TM software (BD Biosciences).
Formulation of NT3 solid particles and encapsulation within microspheres
PLGA microspheres of an average diameter of 60 µm were prepared using a s/o/w emulsion solvent extraction-evaporation process described in [55] , with modifications. Polymer used was a poly(lactic-co-glycolic acid) (PLGA) copolymer with a lactic:glycolic ratio of 37.5:25 (MW: 25,000 Da) (Phusis, Saint Ismier, France).
The protein loading was 1 µg of NT3 (Abcys, Paris, France) with 5 µg of human serum albumin (HSA) (Sigma)/mg of microspheres. First, NT3 and HSA were precipitated separately using a process previously Counter (Beckman Coulter, Roissy, France). Encapsulation yield was determined after dissolution of microspheres in acetone, centrifugation and evaporation, using a NanoOrange® protein quantification kit (Invitrogen, Cergy Pontoise, France) and following the manufacturer's guidelines. To assess the effects of NT3, microspheres without NT3 were also formulated and covered with a biomimetic surface. Thus, in the following, we will distinguish PAMs encapsulating NT3 (PAMs-NT3) and PAMs without NT3 (PAMs-Blank). When no precision is given, the term PAMs refers to both PAMs-NT3 and PAMs-Blank. For technical reasons, microspheres with a reduced diameter (mean of 25 µm) were also formulated to perform zeta potential measurements. We produced these microspheres using the above protocol with increased poly(vinylalcohol) concentration (6 % w/v) and agitation speed (1000 rpm).
Formulation of PAMs
To obtain PAMs, PLGA microspheres were coated with LM. A combination of LM with the highly charged PDL (Sigma) molecules was used to favor cell attachment on PAM surface. 6 mg of microspheres were resuspended in DPBS and sonicated upon full dispersion of the microspheres. Coating solutions were prepared in DPBS, mixed to the microsphere suspension (final volume: 12 mL) and placed under rotation at 15 rpm at 37 °C during 4 hours. After coating, PAMs were washed 3 times in distilled sterile water, lyophilized and finally kept at -20°C for long term storage. Every tube was covered with sigmacote ® (Sigma) to prevent product loss on the tube walls. The final concentration of the coating molecules was 40 µg/mL of LM or of a mixture of PDL/LM.
For optimization of the PDL/LM coating, the ratio PDL-LM of 60/40 was changed to 40/60 after zeta potential evaluation, in order to maximize the quantity of LM adsorbed to the surface. The incubation time was finally decreased to 1.5 hours as well as the total coating molecules concentration (15 µg/mL).
Zeta potential
A Zetasizer 2000 (Malvern Instruments, Orsay, France) operating at 150 V at RT was used to assess PAM electrical surface charge variations depending on the coating used. Briefly, PAMs were redispersed in 10 mL of 1 mM NaCl and sonicated prior to every measurement. The chamber was washed with ultrapure water (Millipore) between every sample. Results are presented as the average ± standard deviation of three experiments and 10 measurements were performed in each experiment.
PAM immunofluorescence
Tubes containing 1 mg coated or uncoated lyophilized PAMs were resuspended in DPBS, 4 % BSA, 0. In vitro NT3 release profile and bioactivity of the released protein NT3 was labeled with 125 I by the iodogen method as previously described [56] . stopped by washing three time with serum containing medium before proceeding to attachment onto PAMs.
Animals and surgical procedures
All animal experiments were conducted in accordance with the "Direction des Services Vétérinaires", 
Behavioral study
Amphetamine-induced rotational behavior was measured in an automated rotometer 11 days after the lesion and 2, 4, 6 & 8 weeks after grafting. The animals were weighed prior to each rotation test. All tests were conducted in a blind manner. 5 mg/kg of D-amphetamine (dissolved in NaCl 0.9%) (Sigma, France) was administered intraperitoneally. Animals were individually placed in circular plastic boxes and attached to the rotational leash 15 min before injection for accustoming. Immediately after amphetamine injection, the test began and the data were recorded for 90 min using a computerized system. A net rotational asymmetry score was expressed as full-body turns per minute in the direction ipsilateral to the lesion. Results are presented as the mean rotations of 5-6 rats per group ± average deviation.
Histological study
Eight weeks after cell transplantation, the animals were anaesthetized and perfused through the heart with 150 ml of ice-cold 0.9 % saline, followed by 300 ml of ice-cold 4 % PFA, 2.5 % sucrose (Sigma) in DPBS 
Statistical analysis
Data are presented as the mean value of three independent experiments ± standard deviation (SD), unless otherwise stated. Significant differences between samples were determined using a Student's t-test Kruskal-Wallis test was used for multiple comparisons. Threshold P-value was set to 0.05, unless otherwise stated.
RESULTS
MIAMI cells integrin subunit screening
In preliminary experiments we observed a higher number 
In vitro neuronal differentiation on laminin vs. fibronectin
We previously demonstrated [11] Importantly, dead cells were never observed during differentiation on either substrate. In addition to a decreased proliferation rate, total cell length was increased in most experiments at the end of differentiation; with longer neurites when plated on LM compared to glass or FN ( figure 1C ).
Finally, we also observed by immunocytofluorescence that at the end of the induction protocol MIAMIderived neuronal-like cells expressed significantly higher levels of β3-Tubulin as well as, to a certain extent, NFM, when plated on LM compared to glass or FN ( figure 1D, E) . We can note that all these trends were also obtained with MIAMI cells not pre-treated with 20 ng/mL of EGF-bFGF, but to a much lower extent (data not shown).
Characterization of PAM biomimetic surface
Uncoated PLGA microspheres and LM-coated PAMs (40 µg/mL) presented a negative zeta potential (figure 2A), which was not satisfactory for cell adhesion. Conversely, PDL-coated PAMs exhibited a positive zeta potential (49.7 ± 2.1 mV). We therefore used a blend of PDL with LM to combine the benefits of a positively charged surface promoting cell adhesion and presenting the ECM molecule. The association of LM with PDL slightly decreased the zeta potential value compared to PDL alone. We next tested conditions allowing to optimize the ratio of PDL/LM, the concentration of coating molecules and the incubation time necessary for adsorption of the molecules on the surface. In this way, the ratio of LM was increased to 60 % instead of 40 %, the adsorption time decreased from 4 to 1.5 hours and the total quantity of coating molecules decreased from 40 µg/mL to 15 µg/mL. We next confirmed these optimized parameters did not impair the positive surface charge, which was 34.5 ± 2.6 mV ( figure 2A, top right bar) , and the homogeneity of the LM surface.
Immunofluorescence imaging demonstrated that no background signal was observed on controls and uncoated microspheres (figure 2B, C) whereas the signal was intense and homogeneous all around the PAMs coated with a mixture of PDL/LM at a ratio of 40/60 ( figure 2D, E) . These optimized conditions were further used throughout this study.
NT3 encapsulation, in vitro release kinetics and bioactivity of the released protein
NT3 loaded microparticles presented a diameter of 57.4 ± 19.0 µm. The yield of the microencapsulation of NT3 was around 100 %, as measured using the NanoOrange® protein quantification kit. The radiolabeling assay demonstrated that around 50 % of the NT3 encapsulated was released in a sustained manner after 22 days, with only a small burst during the first hours. The bioassay performed with MIAMI cells confirmed that the NT3 was released under a bioactive conformation, meaning that the protein remains active through the precipitation/microencapsulation process and throughout the release ( figure 2F ). Thus, we could estimate that about 75 ng of bioactive NT3 could be released in vivo during the first 3 days upon transplantation of 0.75 mg of PAMs, the dose we used in our transplantation experiments.
In vitro characterization of PAMs/DI-MIAMI cell complexes
The LM biomimetic surface allowed the efficient attachment of 1.5x10 5 MIAMI cells on 0.75 mg of PAMs prior to transplantation, as calculated using the Cyquant cell proliferation assay ®. Importantly, almost all the cells attached to the PAM biomimetic surface after 4 hours at 37°C, and no free floating cells were observed ( figure 2G ). RT-qPCR demonstrated that gene expression of Nurr1, DAT and TH was not modified upon attachment to PAMs as observed by RT-qPCR. Only low levels of these markers were detected in MIAMI cells, without significant differences upon early dopaminergic induction (data not shown).
Behavioral study
Amphetamine-induced rotational behavior of sham-treated rats continuously increased from the implantation day until the end of the experiment, at 8 weeks. Implantation of DI-MIAMI cells alone did not significantly reduce the number of ipsilateral rotations compared to sham-treated rats ( figure 3B ). However, transplantation of DI-MIAMI cells adhered onto PAMs-NT3 affected the rotational behavior, which was strongly, and significantly, decreased compared to sham-treated rats or rats implanted with cells alone. In addition, PAMs-Blank resulted in a less important, but still significant, decrease in the animal rotational behavior compared to PAMs-NT3. These observations show a behavioral improvement in rats treated with PAMs/DI-MIAMI cells complexes, while neither improvement nor deterioration was observed in control experiments when grafting PAMs-NT3, but without cells (data not shown).
Protection of nigrostriatal pathway
The rotational behavior was linked to the integrity of the lesioned nigrostriatal pathway, as observed using a rat specific anti-TH immunohistochemistry ( figure 4) . Only a few TH-positive fibres remained in the striatum of sham-treated rats 8 weeks after the lesion (figure 4A), suggesting that the retrograde neurodegeneration progressed in time concomitantly with the increased rotational behavior. The number of neurons in the ipsilateral substantia nigra (SN) was also importantly reduced compared to the contraletaral side.
Transplantation of DI-MIAMI cells in combination with PAMs resulted in a significantly higher density of TH positive fibres in the lesioned striatum (figure 4B, C), therefore demonstrating their neurorepair properties.
However, a higher number of dopaminergic neurons were also observed in the ipsilateral SN in 40 % of the animals, suggesting that a neuroprotection of the nigrostriatal pathway occurred in addition to a repair mechanism due to fibre outgrowth. Transplantation of DI-MIAMI cells without PAMs induced only a small, non significant, protection of the striatal dopaminergic fibres compared to sham-treated rats (data not shown).
Cell fate in vivo
In vitro, the cytoplasmic membrane marker PKH26 did not diffuse to surrounding cells during co- Noteworthy, adhesion onto PAMs tended to increase the expression profile of these molecules by DI-MIAMI cells, as observed by RT-qPCR ( figure 7D, E) . However, the potential role of these molecules in the observed functional recovery would need to be further examined as part of future studies.
DISCUSSION
Adult cells may be easily isolated from the patient body, in particular from accessible tissues (i.e., blood, skin, bone marrow), therefore permitting autologous grafts to be performed in the clinic without ethical problems. For this reason, as well as for their immunomodulatory and tissue repair capacities, their ability to differentiate into neuronal-like cells and to secrete a variety of molecules, the potential of MSCs to treat neurodegenerative disorders, and especially PD, has been recently investigated [5] . However, the percentage of
MSCs that survive and express neural/neuronal markers after transplantation in the brain remains very low [22, 29] . Thus, functional improvements obtained in animal models of PD are thought to primarily derive from the action of growth factors and chemokines produced by transplanted MSCs [27, 28] , which also seems to be the case in several other defects [58] [59] [60] . Tissue engineering may be of great interest to help repair lesioned tissues/organs due to the possible increase in grafted cell survival, differentiation, or secretory profile induced by the supportive element or scaffold. In this study, we used carriers providing a biomimetic support and the delivery of a growth factor, the PAMs, combined with MIAMI cells to maximize the resulting protective/reparative effects on hemi-parkinsonian rats. We here demonstrated the efficacy of this tool in a rat model of PD, as an important motor function recovery was observed upon grafting with PAMs/DI-MIAMI cell complexes, while no major effects were observed with DI-MIAMI cells alone. This behavioral recovery upon attachment of MIAMI cells to PAMs was correlated with a neuroprotection/repair of the nigrostriatal pathway.
These effects were mainly due to the increased survival and engraftment of transplanted cells which secrete a variety of neurotrophic factors and chemokines. Moreover, a fraction of the cells transplanted with the PAMs expressed human TH, strongly suggesting a neuronal dopaminergic phenotype. Therefore, these cells may have produced dopamine, which could have contributed to functional improvement. We thus demonstrate that the PAMs enhance the stem cell repair capacity by improving their survival and differentiation, as we previously observed with PC12 cells and embryonic dopaminergic cells [47, 48] .
To improve the known potential of MIAMI cells to differentiate toward a neuronal lineage [16] [11], we studied their neuronal differentiation in vitro on 2 ECM molecules, FN and LM, for which the cells express a high level of integrin receptors [61] . Indeed, LM is known to induce Nestin expression, a marker of neuronal precursors, in MSCs [43] as well as morphological changes during neuronal differentiation, with a higher number of neurite-like branching [42] . In our hands, MIAMI cells differentiated on a substrate of LM in vitro exhibited longer neurite-like extensions together with an improved expression of neuronal proteins (β3-Tubulin and NFM, respectively) compared to FN. Noteworthy, no cell body retraction was observed upon culture on a LM substrate, therefore confirming that the increased expression of β3-Tubulin and NFM were not artifacts due to cellular shrinkage as it has sometimes been suggested [62, 63] . Moreover, cell proliferation was almost abolished when cells were differentiated on LM. All these observations are commonly related to a normal stem cell differentiation process, thereby suggesting the bioactive signalling role of LM in the induction of MIAMI cells toward a neuronal lineage.
A biomimetic scaffold bearing LM should therefore be advantageous to implement MIAMI cell therapy in a context where an efficient neuronal differentiation is required. PAMs covered with LM alone presented a weak cell adhesion property so we designed PAMs with a surface made of LM blended with the highly charged PDL molecules. Addition of PDL to the LM surface efficiently switched the zeta potential of PAMs toward positive value, without detriment to LM distribution homogeneity around PAMs. From a practical point of view, formulation of PAM surface was optimized for easier implementation within future potential clinical studies, resulting in a shorter (from 4 hours to 1.5 hours) but also less expensive protocol as less protein was used without affecting surface characteristics in terms of zeta potential and homogeneity. Moreover, reducing LM adsorption time prevented an excessive loss of NT3 during formulation as a small burst release was observed during the first hours, as is usually the case from PLGA microspheres [55] . In addition to the use of a LM biomimetic surface, PAMs may further enhance MIAMI cells survival and neuronal differentiation by releasing neurotrophin 3, a factor known to play a role in this process [16] . This neurotrophin was encapsulated with a high efficiency within PAMs (100 % encapsulation yield) and could be released in a prolonged manner under a bioactive conformation, with only a small burst during the first hours. Around 50 % of the encapsulated protein was released after 22 days, suggesting that NT3 could have a long term effect in vivo.
As reported earlier, PAMs may improve the integration of PC12 cells and embryonic dopaminergic cells within the brain parenchyma, after transplantation in hemi-parkinsonian rats, by improving their survival and differentiation [47, 48] . An improved differentiation of MSCs toward a chondrogenic phenotype in combination with TGFβ3 PAMs, has also recently been described in vitro and in vivo [46] . In a similar manner, use of PAMs-NT3 in our study led to a 3 fold increased survival of DI-MIAMI cells 8 weeks after transplantation in hemi-parkinsonian rats, while PAMs-Blank only induced a 2 fold increase in cell survival compared to DI-MIAMI cells grafted alone. This result suggests that bioactive NT3 is being released from the PAMs in vivo, which contributes to the survival and differentiation of MIAMI cells and their induced functional recovery. Thus, PAMs could be an easy way to improve the low survival usually observed in long term studies when grafting MSCs in PD rat brains [26] [27] [28] [29] . In addition to an increased survival, PAMs induced the differentiation of a fraction of DI-MIAMI cells, with TH expression observed 8 weeks after transplantation of the complexes, but not in the case of cells transplanted alone. Finally, these complexes successfully promoted a reduction of the amphetamine-induced rotational behavior, while cells alone did not induce a major recovery. A small fraction of TH-expressing human MSCs have already been described by another team in the context of PD [29] , and the functional recovery they observed in the context of a total nigrostriatal lesion underlined the ability of human MSCs to produce dopamine in situ. Another study described functional improvements obtained by grafting dopaminergic-induced human MSCs in the same animal model of Parkinson's disease [27] as ours, despite an incomplete neuronal engagement in vitro, as is the case in our study. Thus, these authors concluded that the functional effects observed should mainly derive from secretion of growth factors, chemokines or cytokines from the transplanted cells, a property they previously observed in vitro [64] . This is also certainly the case in our study, although dopamine production by TH expressing cells in presence of PAMs may also have contributed to the functional effect we observed.
In addition to the increased survival/differentiation of grafted cells, the functional effect observed in our study was correlated with a neuroprotection/reparation of the nigrostriatal pathway. This neuroprotection/repair process cannot be observed in studies using total nigrostriatal lesion models [16, 29] , in which the functional benefits are mainly derived from the secretion of dopamine by the transplanted cells. A repair of the nigrostriatal fibres has already been reported after GDNF striatal injection in not only pre-clinical but also clinical studies [65] , and more recently with GDNF delivering microspheres (without cells) enabling the prolonged delivery of the factor [65] [66] [67] [68] . Adhesion of DI-MIAMI cells to PAMs-NT3 induced an increased survival of cells but also resulted in an increased expression of GDNF and Stanniocalcin 1 mRNAs. Therefore, in our study, a repair mechanism based on fibre sprouting and possibly driven by the secretion of growth factors such as GDNF may explain the high density of TH-positive fibres detected in the striatum with only a few TH-positive neurons in the substantia nigra. In comparison to the use of GDNF releasing scaffolds, our strategy advantageously results in the secretion of multiple growth factors and chemokines by surviving cells, with potential long-term effects.
Importantly, combination of PAMs with DI-MIAMI cells not only led to repair but also to neuroprotection of the nigrostriatal pathway in 40 % of the animals, with TH-positive fibres and neurons surviving in the striatum and in the substantia nigra after 8 weeks. This protection was also probably due to the secretion of growth factors and chemokines by the transplanted cells. Accordingly, Stanniocalcin 1 may have a role in protecting surrounding cells from apoptosis [69] .
In opposition to DI-MIAMI cells, MIAMI cells only pre-treated with EGF-bFGF efficiently promoted a functional recovery, despite a poor survival due to the absence of PAMs. This observation confirms the potential of EGF-bFGF pre-treated cells for brain cell therapy [11] and supports the hypothesis that functional recovery mainly derives from secretion of growth factors, chemokines or cytokines from the transplanted cells. For example, it is now known that EGF-bFGF treatment increase the secretion of BDNF, GDNF and NGF by adipocyte-derived MSCs, an ability supposed to be responsible for the functional recovery the authors observed [30] . In a similar manner, we demonstrated that EGF-bFGF pre-treated MIAMI cells did produce a significantly higher amount of GDNF and Stanniocalcin 1 compared to MIAMI cells that were furthermore differentiated toward the dopaminergic lineage.
CONCLUSION
To conclude, PAMs-NT3 transporting MIAMI cells induced a strong functional recovery in rat models of PD, mainly via an improved survival and differentiation of grafted cells. Moreover, the secretion pattern of relevant neuroprotecting/repairing factors by MIAMI cells was positively modified upon combination with
PAMs. These factors, secreted by surviving cells, may be responsible for the neuroprotection/repair of the nigrostriatal pathway observed, while a possible secretion of dopamine by differentiated cells could have also contributed to the functional effects. This adult cell therapy study demonstrates the benefits of biomaterials combining the biomimetic strategy with the controlled delivery of a growth factor to treat PD [5] . After deeper characterization of the underlying mechanisms, this tissue engineering strategy may ultimately set the ground for pre-clinical studies with non-human primates to increase the efficiency of MSC therapy of the brain.
